| Item Type | Name |
|
Concept
|
Placenta Growth Factor
|
|
Concept
|
Tumor Necrosis Factor alpha-Induced Protein 3
|
|
Concept
|
Fibrinogen
|
|
Concept
|
Rheumatoid Factor
|
|
Concept
|
Complement Factor H
|
|
Concept
|
Stem Cell Factor
|
|
Concept
|
Receptors, Tumor Necrosis Factor
|
|
Concept
|
Receptor, Platelet-Derived Growth Factor alpha
|
|
Concept
|
Complement Factor B
|
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Receptors, Tumor Necrosis Factor, Type I
|
|
Concept
|
Receptors, Tumor Necrosis Factor, Type II
|
|
Concept
|
TNF Receptor-Associated Factor 6
|
|
Concept
|
B-Cell Activating Factor
|
|
Concept
|
Tumor Necrosis Factor Ligand Superfamily Member 13
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-1
|
|
Concept
|
Core Binding Factor Alpha 3 Subunit
|
|
Concept
|
STAT1 Transcription Factor
|
|
Concept
|
STAT3 Transcription Factor
|
|
Concept
|
STAT4 Transcription Factor
|
|
Concept
|
Interferon Regulatory Factor-7
|
|
Concept
|
Ikaros Transcription Factor
|
|
Academic Article
|
Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms.
|
|
Academic Article
|
Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans.
|
|
Academic Article
|
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
|
|
Academic Article
|
High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups.
|
|
Academic Article
|
Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells.
|
|
Academic Article
|
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
|
|
Academic Article
|
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
|
|
Academic Article
|
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.
|
|
Academic Article
|
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.
|
|
Academic Article
|
Immunologic findings precede rapid lupus flare after transient steroid therapy.
|
|
Academic Article
|
BLyS antagonists and peptide tolerance induction.
|
|
Academic Article
|
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls.
|
|
Academic Article
|
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility.
|
|
Academic Article
|
Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare.
|
|
Academic Article
|
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
|
|
Academic Article
|
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
|
|
Academic Article
|
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.
|
|
Academic Article
|
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
|
|
Academic Article
|
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
|
|
Academic Article
|
A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus.
|
|
Academic Article
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
|
|
Academic Article
|
B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.
|
|
Academic Article
|
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study.
|
|
Academic Article
|
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
|
|
Academic Article
|
Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells.
|
|
Academic Article
|
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks.
|
|
Academic Article
|
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.
|
|
Academic Article
|
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus.
|
|
Academic Article
|
Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus.
|
|
Academic Article
|
Evaluation of TRAF6 in a large multiancestral lupus cohort.
|
|
Academic Article
|
Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A.
|
|
Academic Article
|
Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
|
|
Academic Article
|
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications.
|
|
Academic Article
|
Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.
|
|
Grant
|
SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
|
|
Grant
|
SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
|
|
Academic Article
|
Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients.
|
|
Academic Article
|
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
|
|
Academic Article
|
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
|